B14. How Clinical Trial Service Providers Influence Outcomes
Tracks
Clinical Research
| Wednesday, June 4, 2025 |
| 2:45 PM - 3:45 PM |
| C2.2+C2.3 |
Chair & Speakers
Simon Dixon
Director, Commercial Services
Sonic Clinical Trials
How Clinical Trial Service Providers Influence Outcome
Biography
Marcin Drag
Head of Clinical
Smartways Logistics
How Clinical Trial Service Providers Influence Outcome
Abstract
The success of a clinical trial depends on much more than groundbreaking science, brilliant minds, and rigorous laboratory work. Service providers play a pivotal role in shaping the trajectory of a trial, influencing everything from operational efficiency to regulatory success.
With only about 1 in 20,000 drug candidates reaching commercialisation, trial failures are often not due to poor science but rather operational, logistical, and strategic challenges. Choosing the right service providers is a key factor in ensuring positive outcomes, affecting budgets, timelines, quality standards, team morale, and ultimately, regulatory approval.
This panel brings together some of the industry’s most respected clinical trial service providers to discuss their impact on trial outcomes and the crucial considerations in vendor selection. While legacy players have long dominated the space, technological advancements, lessons learned from past failures, and the need for greater flexibility are refreshingly, reshaping the landscape.
In an industry dedicated to breakthroughs that improve patient lives, collaborating with partners who can support and enhance your work is essential. Join us to hear from experts who are helping to drive the future of clinical trials forward.
With only about 1 in 20,000 drug candidates reaching commercialisation, trial failures are often not due to poor science but rather operational, logistical, and strategic challenges. Choosing the right service providers is a key factor in ensuring positive outcomes, affecting budgets, timelines, quality standards, team morale, and ultimately, regulatory approval.
This panel brings together some of the industry’s most respected clinical trial service providers to discuss their impact on trial outcomes and the crucial considerations in vendor selection. While legacy players have long dominated the space, technological advancements, lessons learned from past failures, and the need for greater flexibility are refreshingly, reshaping the landscape.
In an industry dedicated to breakthroughs that improve patient lives, collaborating with partners who can support and enhance your work is essential. Join us to hear from experts who are helping to drive the future of clinical trials forward.
Biography
Sue MacLeman
Non Executive Director
Smartways
How Clinical Trial Service Providers Influence Outcome
Abstract
The success of a clinical trial depends on much more than groundbreaking science, brilliant minds, and rigorous laboratory work. Service providers play a pivotal role in shaping the trajectory of a trial, influencing everything from operational efficiency to regulatory success.
With only about 1 in 20,000 drug candidates reaching commercialisation, trial failures are often not due to poor science but rather operational, logistical, and strategic challenges. Choosing the right service providers is a key factor in ensuring positive outcomes, affecting budgets, timelines, quality standards, team morale, and ultimately, regulatory approval.
This panel brings together some of the industry’s most respected clinical trial service providers to discuss their impact on trial outcomes and the crucial considerations in vendor selection. While legacy players have long dominated the space, technological advancements, lessons learned from past failures, and the need for greater flexibility are refreshingly, reshaping the landscape.
In an industry dedicated to breakthroughs that improve patient lives, collaborating with partners who can support and enhance your work is essential. Join us to hear from experts who are helping to drive the future of clinical trials forward.
With only about 1 in 20,000 drug candidates reaching commercialisation, trial failures are often not due to poor science but rather operational, logistical, and strategic challenges. Choosing the right service providers is a key factor in ensuring positive outcomes, affecting budgets, timelines, quality standards, team morale, and ultimately, regulatory approval.
This panel brings together some of the industry’s most respected clinical trial service providers to discuss their impact on trial outcomes and the crucial considerations in vendor selection. While legacy players have long dominated the space, technological advancements, lessons learned from past failures, and the need for greater flexibility are refreshingly, reshaping the landscape.
In an industry dedicated to breakthroughs that improve patient lives, collaborating with partners who can support and enhance your work is essential. Join us to hear from experts who are helping to drive the future of clinical trials forward.
Biography
Dr Michele Stokes
Executive Director, General Manager
PCI Pharma Services
How Clinical Trial Service Providers Influence Outcome
Abstract
The success of a clinical trial depends on much more than groundbreaking science, brilliant minds, and rigorous laboratory work. Service providers play a pivotal role in shaping the trajectory of a trial, influencing everything from operational efficiency to regulatory success.
With only about 1 in 20,000 drug candidates reaching commercialisation, trial failures are often not due to poor science but rather operational, logistical, and strategic challenges. Choosing the right service providers is a key factor in ensuring positive outcomes, affecting budgets, timelines, quality standards, team morale, and ultimately, regulatory approval.
This panel brings together some of the industry’s most respected clinical trial service providers to discuss their impact on trial outcomes and the crucial considerations in vendor selection. While legacy players have long dominated the space, technological advancements, lessons learned from past failures, and the need for greater flexibility are refreshingly, reshaping the landscape.
In an industry dedicated to breakthroughs that improve patient lives, collaborating with partners who can support and enhance your work is essential. Join us to hear from experts who are helping to drive the future of clinical trials forward.
With only about 1 in 20,000 drug candidates reaching commercialisation, trial failures are often not due to poor science but rather operational, logistical, and strategic challenges. Choosing the right service providers is a key factor in ensuring positive outcomes, affecting budgets, timelines, quality standards, team morale, and ultimately, regulatory approval.
This panel brings together some of the industry’s most respected clinical trial service providers to discuss their impact on trial outcomes and the crucial considerations in vendor selection. While legacy players have long dominated the space, technological advancements, lessons learned from past failures, and the need for greater flexibility are refreshingly, reshaping the landscape.
In an industry dedicated to breakthroughs that improve patient lives, collaborating with partners who can support and enhance your work is essential. Join us to hear from experts who are helping to drive the future of clinical trials forward.
Biography
Mr George Vlachos
Co-CEO
Akesa
How Clinical Trial Service Providers Influence Outcome
Abstract
The success of a clinical trial depends on much more than groundbreaking science, brilliant minds, and rigorous laboratory work. Service providers play a pivotal role in shaping the trajectory of a trial, influencing everything from operational efficiency to regulatory success.
With only about 1 in 20,000 drug candidates reaching commercialisation, trial failures are often not due to poor science but rather operational, logistical, and strategic challenges. Choosing the right service providers is a key factor in ensuring positive outcomes, affecting budgets, timelines, quality standards, team morale, and ultimately, regulatory approval.
This panel brings together some of the industry’s most respected clinical trial service providers to discuss their impact on trial outcomes and the crucial considerations in vendor selection. While legacy players have long dominated the space, technological advancements, lessons learned from past failures, and the need for greater flexibility are refreshingly, reshaping the landscape.
In an industry dedicated to breakthroughs that improve patient lives, collaborating with partners who can support and enhance your work is essential. Join us to hear from experts who are helping to drive the future of clinical trials forward.
With only about 1 in 20,000 drug candidates reaching commercialisation, trial failures are often not due to poor science but rather operational, logistical, and strategic challenges. Choosing the right service providers is a key factor in ensuring positive outcomes, affecting budgets, timelines, quality standards, team morale, and ultimately, regulatory approval.
This panel brings together some of the industry’s most respected clinical trial service providers to discuss their impact on trial outcomes and the crucial considerations in vendor selection. While legacy players have long dominated the space, technological advancements, lessons learned from past failures, and the need for greater flexibility are refreshingly, reshaping the landscape.
In an industry dedicated to breakthroughs that improve patient lives, collaborating with partners who can support and enhance your work is essential. Join us to hear from experts who are helping to drive the future of clinical trials forward.
Biography
With a career spanning over 25 years, George Vlachos is renowned for his expertise and leadership in the pharmaceutical industry.
As Co-Founder and Co-CEO of Akesa, George's focus on global sourcing and procurement of comparator pharmaceutical products has been crucial in navigating the complex challenges of clinical trial management. His proactive approach and vast network enhance Akesa’s capabilities in securing essential pharmaceuticals, ensuring the highest standards of quality in clinical operations.
George has a deep knowledge of the clinical trial supply chain and its associated complexities, developed across his vast career working at industry giants including contract research organisation (CRO) PPD and IQVIA, and with global pharmaceutical company Eli Lilly.
During his early career, George excelled in managing large scale clinical trials across APAC as Region Project Manager and developed a clinical trial distribution depot and GMP facility in Australia.
In recent years, George has expanded his focus to encompass the commercial pharmaceutical supply chain. The pharmaceutical supply chain management market has experienced robust growth due to the rise in clinical trials across APAC and the increasing demand pharmaceutical of products.
George led the integration of commercial pharmaceutical supply chain software into Akesa's operations, improving all aspects of clinical trial supply. George is committed to improved processes, innovation and excellence in pharmaceutical supply chain management.
